Cargando…

Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog

In vitro cytotoxicity of tafluprost, which is the most recently developed anti-glaucoma prostaglandin (PG) analog, in ocular surface cells is addressed in comparison with other PG analogs. Irrespective of cell lines and models, the cytotoxicity of anti-glaucoma PG eyedrops was primarily related to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niwano, Yoshimi, Iwasawa, Atsuo, Ayaki, Masahiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928056/ https://www.ncbi.nlm.nih.gov/pubmed/24558301 http://dx.doi.org/10.4137/OED.S12445

Ejemplares similares

Comparative assessment of the cytotoxicity of six anti-inflammatory eyedrops in four cultured ocular surface cell lines, as determined by cell viability scores
por: Ayaki, Masahiko, et al.
Publicado: (2012)

Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines
por: Ayaki, Masahiko, et al.
Publicado: (2010)

Protective effects of blue light-blocking shades on phototoxicity in human ocular surface cells
por: Niwano, Yoshimi, et al.
Publicado: (2019)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate, Ngamkae, et al.
Publicado: (2020)

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
por: Horsley, Michael B, et al.
Publicado: (2009)

Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy
por: Kitamura, Kazuyoshi, et al.
Publicado: (2018)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
por: Hommer, Anton, et al.
Publicado: (2011)

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Pozarowska, Dorota
Publicado: (2010)

Tafluprost for the Reduction of Interocular Pressure in Open Angle Glaucoma and Ocular Hypertension
por: Schultz, Clyde
Publicado: (2011)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
por: Lanzl, Ines, et al.
Publicado: (2013)

A Pooled Assessment of Ocular Surface Disease After Switching from Preserved Prostaglandins to Tafluprost Across Six Countries in Asia
por: Tumbocon, Joseph Anthony, et al.
Publicado: (2022)

Cytotoxicity of five fluoroquinolone and two nonsteroidal anti-inflammatory benzalkonium chloride-free ophthalmic solutions in four corneoconjunctival cell lines
por: Ayaki, Masahiko, et al.
Publicado: (2010)

Comparison of Efficacy and Ocular Surface Disease Index Score between Bimatoprost, Latanoprost, Travoprost, and Tafluprost in Glaucoma Patients
por: El Hajj Moussa, Wissam Georges, et al.
Publicado: (2018)

Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2018)

Effects of Tafluprost on Ocular Blood Flow
por: Zhang, Xinyue, et al.
Publicado: (2022)

Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
por: Wong, Tina T, et al.
Publicado: (2018)

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
por: Ermiş, Sıtkı Samet
Publicado: (2012)

Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China
por: Sun, Xinghuai, et al.
Publicado: (2022)

Influence of BAK-Preserved Prostaglandin Analog Treatment on the Ocular Surface Health in Patients with Newly Diagnosed Primary Open-Angle Glaucoma
por: Tomić, Martina, et al.
Publicado: (2013)

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
por: Tokuda, Naoto, et al.
Publicado: (2017)

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
por: Aihara, Makoto
Publicado: (2010)

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
por: Takagi, Yasutaka, et al.
Publicado: (2018)

Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
por: Ayaki, Masahiko, et al.
Publicado: (2010)

Dry eye, sleep quality, and mood status in glaucoma patients receiving prostaglandin monotherapy were comparable with those in non-glaucoma subjects
por: Ra, Shugyoku, et al.
Publicado: (2017)

In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study
por: Kim, Jee Hyun, et al.
Publicado: (2015)

The clinical effectiveness of tafluprost on Japanese normal-tension glaucoma patients
por: Nomura, Akio, et al.
Publicado: (2018)

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
por: Schnober, Dietmar, et al.
Publicado: (2010)

Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs
por: Schmier, Jordana K, et al.
Publicado: (2014)

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension
por: Topouzis, Fotis, et al.
Publicado: (2019)

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2013)

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products
por: Holló, Gábor, et al.
Publicado: (2014)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
por: Nakamoto, Kenji, et al.
Publicado: (2018)

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
por: Park, Sang-Woo, et al.
Publicado: (2022)

A Prospective Study Evaluating IOP Changes after Switching from a Therapy with Prostaglandin Eye Drops Containing Preservatives to Nonpreserved Tafluprost in Glaucoma Patients
por: Ranno, Stefano, et al.
Publicado: (2012)

Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety
por: Takagi, Yasutaka, et al.
Publicado: (2016)

Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma
por: Ikeda, Yoko, et al.
Publicado: (2016)

Correction to: Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
por: Hwang, Young Hoon
Publicado: (2014)

Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study
por: Esaki, Yoshihiko, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dlbckp3kfeim2cvot0q7ma6rqb